Table 1 Final model stratified on landmark at time intervals from day of allo-HCT to day + 360 by 30 days

No acute GVHD (n = 320, ref.)

1

1

1

1

Acute GVHD I (n = 144)

0.82 (0.56–1.21)

0.53 (0.27–1.01)

0.71 (0.51–0.99)

0.68 (0.48–0.97)

0.032

Acute GVHD II (= 117)

0.83 (0.54–1.26)

0.78 (0.4–1.52)

0.8 (0.56–1.15)

0.86 (0.6–1.24)

0.42

Acute GVHD III–IV (n = 89)

0.87 (0.55–1.36)

3.09 (1.87–5.12)

1.36 (0.99–1.86)

1.32 (0.88–1.97)

0.17

No cGVHD (reference)

1

1

1

1

Limited cGVHD

0.8 (0.43–1.49)

1.23 (0.54–2.81)

0.93 (0.57–1.52)

0.84 (0.48–1.49)

0.56

Extensive cGVHD

1.34 (0.74–2.42)

3.3 (1.81–6.04)

1.97 (1.35–2.89)

1.95 (1.29–2.94)

0.001

Age (per 10 y)*

0.9 (0.82–0.99)

1.56 (1.27–1.92)

1.03 (0.94–1.13)

1.07 (0.98–1.18)

0.14

Sec. AML*

0.79 (0.54–1.15)

0.87 (0.52–1.46)

0.85 (0.63–1.15)

0.94 (0.69–1.28)

0.7

Adverse cytogenetics*

1.83 (1.37–2.45)

1.33 (0.86–2.06)

1.68 (1.32–2.13)

1.65 (1.28–2.12)

0.0001

Year of HCT*

0.97 (0.92–1.03)

0.97 (0.88–1.07)

0.97 (0.93–1.02)

0.98 (0.93–1.03)

0.42

KPS90*

0.88 (0.67–1.16)

0.61 (0.4–0.93)

0.82 (0.65–1.02)

0.82 (0.64–1.04)

0.11

Female to male*

0.8 (0.56–1.15)

1.43 (0.9–2.28)

0.97 (0.74–1.26)

1.08 (0.81–1.44)

0.58

Patient CMV positive*

1.19 (0.84–1.68)

1.01 (0.63–1.64)

1.12 (0.85–1.48)

1.11 (0.83–1.47)

0.49

Donor CMV positive*

1.14 (0.85–1.53)

0.73 (0.47–1.14)

1 (0.78–1.27)

1.02 (0.79–1.33)

0.86

PB vs BM*

0.94 (0.69–1.28)

1.66 (1.01–2.72)

1.07 (0.83–1.39)

1.1 (0.84–1.45)

0.47

RIC vs MAC*

1.11 (0.83–1.5)

0.88 (0.52–1.46)

1.06 (0.82–1.38)

1.15 (0.87–1.52)

0.33

In vivo TCD*

1.59 (1.03–2.44)

0.89 (0.4–1.97)

1.34 (0.9–1.99)

1.28 (0.86–1.92)

0.22